The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
|Articles|July 1, 2006
Cream by Day, Ointment by Night
Patients often complain that ointments are greasy and stain clothing. Here's how to solve the problem and encourage compliance.
Advertisement
Ointments are an effective vehicle for topical treatment of such chronic dermatologic conditions as eczema and psoriasis; however, patients often complain that they are greasy and stain clothing. I find that prescribing an ointment for nighttime application and a cream for use during the day results in better compliance.
- Benjamin Barankin, MD
Toronto
Advertisement
Related to this article
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
2
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
3
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
4
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
5